NCT02663895View on ClinicalTrials.gov

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

May 13, 2020

Study Completion Date

May 13, 2020

Conditions
Systemic SclerosisCalcinosis
Interventions
DRUG

Oral treprostinil

Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated

Trial Locations (1)

94304

Stanford University School of Medicine, Palo Alto

Sponsors

Collaborators (1)

United Therapeutics
All Listed Sponsors
collaborator

United Therapeutics

INDUSTRY

lead

Stanford University

OTHER